Loading...
In this double-blind, placebo-controlled trial, researchers administered botulinum toxin type A (Botox) to patients with chronic regional neuropathic pain and mechanical allodynia, caused in 25 by nerve trauma and in 4 by postherpetic neuralgia. After a single round of regional intradermal injections, the investigators periodically tested patients’ spontaneous pain intensity (the primary outcome) during 24 weeks of follow-up. Secondary outcomes included response to quantitative sensory testing and brush allodynia.
According to post hoc analyses, during weeks 2 through 14 the Botox group had significantly greater reductions from baseline in weekly-averaged spontaneous pain intensity than did the placebo group. Secondary-outcome improvements i…